WEBULL
WebtradeDownload

Gilead Sciences (GILD) Tests Its Multi Platform Story On Questions Around Valuation

Simply Wall St · 1d ago

Gilead Sciences (GILD) is back in focus after securing a $2.5 million federal grant with research partners to pursue oral treatments for mosquito-borne flaviviruses, spotlighting the stock’s broader infectious disease pipeline.

Recent moves in Gilead Sciences reflect that backdrop. The share price has gained 20.09% over the past 90 days and 24.41% year to date, while the 1-year total shareholder return of 39.66% and 5-year total shareholder return of 168.20% point to momentum that has been building rather than fading.

Scan for other infectious disease and HIV-focused opportunities that are moving on similar catalysts by using our curated list of 35 healthcare AI stocks aligned with treatment breakthroughs and pipeline momentum.

Gilead Sciences now trades only modestly below average analyst targets, yet at a steep discount to some intrinsic value models. After this sharp run, is the market’s caution about future cash flows misplaced or exactly right?

Most Popular Narrative: 17.8% Overvalued

The most followed Gilead Sciences narrative pegs fair value at $128.38, which sits well below the recent $151.28 close. As a result, the current price carries a clear premium to that framework.

Gilead is transitioning from a “single-franchise HIV company” into a multi-platform biopharma with high-probability growth drivers (lenacapavir, Trodelvy) and high-upside optionality (cell therapy, immunology). Temporary earnings headwinds are masking long-term value creation.

See why 18 investors see Gilead Sciences as 18% overvalued.

Result: Fair Value of $128.38 (OVERVALUED)

Still, this storyline can crack if key trials underwhelm or if acquisition driven EPS pressure and the recent net loss continue to weigh on confidence.

Find out about the key risks to this Gilead Sciences narrative.

Another View: Our Gilead Sciences DCF Signal

The most popular Gilead Sciences narrative leans on a $128.38 fair value that screens the stock as 17.8% overvalued. Our DCF model points the other way, with a future cash flow value of $309.33, which implies GILD trades at a 51.1% discount. Which framework feels more credible for you?

To see how that cash flow based estimate is built step by step, Look into how the SWS DCF model arrives at its fair value.

GILD Discounted Cash Flow as at Sep 2026
GILD Discounted Cash Flow as at Sep 2026

Next Steps

Mixed signals around Gilead Sciences can be confusing. Move quickly, review the underlying numbers, and weigh both sides of the story with 3 key rewards and 2 important warning signs

Looking for more investment ideas beyond Gilead Sciences?

Do not stop with Gilead Sciences. Use the Simply Wall St Screener to hunt for fresh opportunities that fit your risk, income, and value priorities.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.